Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CST-101, CST-103, and CST-109 CNS effects study in healthy adults and Parkinson's disease
NL-OMON48526Completed
- Sponsor
- CuraSen Therapeutics
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of CST-101, clenbuterol and CST-109 in Parkinson's disease (PD) (4 arms), sponsored by CuraSen Therapeutics. Primary endpoints: Saccadic eye movement, Smooth pursuit eye movement and 11 more. Started Aug 2019; status: completed.
02
Drugs
CST-101clenbuterolCST-109
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON48526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48526.